Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

• Main Authors: Passaro, A., Wang, J., Wang, Y., Lee, S. -H., Melosky, B., Shih, J. -Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A. B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J. -l., Salinas, J., Tomasini, P., Gentzler, R. D., William, W. N., Reckamp, K. L., Takahashi, T., Ganguly, S., Kowalski, D. M., Bearz, A., MacKean, M., Barala, P., Bourla, A. B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R. E., Bauml, J. M., Campelo, R. G., Cho, B. C., Investigators, MARIPOSA-2
• Format: Article
• Published: Elsevier 2024
• Subjects: R Medicine (General)
• Online Access: http://eprints.um.edu.my/45788/; https://doi.org/10.1016/j.annonc.2023.10.117
• Institution: Universiti Malaya

Background: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-smallcell lung cancer (NSCLC) in phase I studies. These combinations were evaluated...